Valuation: Alkermes plc

Market Cap 8.66B 7.59B 7.03B 6.47B 12.24B 829B 12.48B 83.82B 32.87B 407B 32.51B 31.8B 1,405B P/E 2026 *
-135x
P/E 2027 * 89.2x
Enterprise Value 9.67B 8.48B 7.85B 7.22B 13.67B 925B 13.93B 93.58B 36.7B 454B 36.3B 35.5B 1,569B EV / Sales 2026 *
5.34x
EV / Sales 2027 * 4.98x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week-6.72%
Current month-1.83%
1 month+15.95%
3 months+52.40%
6 months+76.45%
Current year+83.83%
1 week 50.54
Extreme 50.54
55.67
1 month 43.34
Extreme 43.34
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Compliance Officer

-2,034 0.0012%
06-30Fiscal year

Chief Technology Officer

19,000 0.0114%
06-11Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%-6.72%+73.24%+71.39% 8.66B
+0.44%+1.41%+4.25%+10.81% 50.73B
-2.86%-4.68%+371.98%+582.62% 39.73B
+0.81%+1.72%+30.84%-4.61% 34.69B
+1.55%-1.94%+20.35%+53.13% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-2.07%-1.66% - - 16.8B
-0.88%-5.81%+66.14%+121.38% 15.37B
+0.78%+1.16%+15.53%+17.32% 13.78B
-0.18%-2.35%+11.64%-32.96% 12.85B
Average -0.34%-1.36%+66.32%+94.53% 25.26B
Weighted average by Cap. -0.28%-0.53%+79.88%+120.65%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.47B 1.35B 2.56B 173B 2.61B 17.52B 6.87B 85.04B 6.79B 6.65B 294B 1.89B 1.66B 1.53B 1.41B 2.67B 181B 2.72B 18.29B 7.18B 88.81B 7.1B 6.94B 307B
Net income -64.62M -56.68M -52.49M -48.3M -91.36M -6.18B -93.14M -626M -245M -3.04B -243M -237M -10.49B 101M 88.17M 81.66M 75.14M 142M 9.62B 145M 973M 382M 4.72B 377M 369M 16.32B
Net Debt 1.01B 884M 819M 754M 1.43B 96.52B 1.45B 9.76B 3.83B 47.4B 3.79B 3.7B 164B 757M 664M 615M 566M 1.07B 72.49B 1.09B 7.33B 2.88B 35.6B 2.84B 2.78B 123B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
13/07/26 US$51.49 -0.88% 800,322
10/07/26 US$51.94 -3.42% 1,691,454
09/07/26 US$53.78 -0.94% 1,630,543
08/07/26 US$54.29 -1.68% 1,706,011
07/07/26 US$55.22 +0.15% 1,719,310
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
51.94USD
Average target price
51.12USD
Spread / Average Target
-1.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock